Abstract
Purpose. To determine if early cancer size reduction seen on enhanced magnetic resonance imaging (MRI) can serve as a response predictor and to correlate final tumor sizes on MRI and excised gross tumor size to microscopic findings in patients with locally advanced breast cancers treated with preoperative neoadjuvant chemotherapy.
Methods and materials. Thirty-three patients with advanced breast cancer entered this prospective chemotherapeutic study. Serial, dynamic, enhanced MRI was performed before chemotherapy induction, after the first course of chemotherapy and after the third course of chemotherapy prior to surgery. Responses were measured by image subtraction of tumor size on subsequent axial MRIs using the response evaluation criteria in solid tumors (RECIST). Early tumor size reduction, percentage of relative early tumor size reduction and final tumor size response were calculated and analyzed statistically. Sizes of residual tumors measured on MRI and gross tumors in excised breasts were correlated with microscopic findings.
Results. Based on tumor sizes measured with enhanced MRI, four complete responders (CR), 19 partial responders (PR) and 10 non-responder were documented. Twelve (52%) of the 23 responders (CR and PR) had reached the criteria for PR (≥30% size reduction) after the first course of chemotherapy. All CR had a marked early size reduction (ESR) of more than 45%. Using the receiver operating characteristic (ROC) curve, a good cutoff point for early tumor size reduction was 7.4 cm, with a false positive rate of 0.1 and a false negative rate of 0.13. The percentage of ESR was 8.8%, with a false positive rate of 0.1 and a false negative rate of 0.09. Residual tumor size on MRI correlated well with microscopic findings (r = 0.982, p < 0.001) and gross tumor size in excised breasts correlated moderately with microscopic findings (r = 0.640, p < 0.001).
Conclusion. Serial, dynamic, enhanced MRI monitoring of chemotherapeutic response in patients with locally advanced breast cancer can be used to assess early response to chemotherapy and post-chemotherapy tumor size change. Although the residual tumor size on MRI correlated well with the microscopic findings, surgical determination of residual cancer load is still recommended to avoid underestimation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bonadonna G: Conceptual and practical advanced in the management of breast cancer. J Clin Oncol 7: 1380-1397, 1989
Schwartz GF, Cantor RI, Biermann WA: Neoadjuvant chemotherapy before definite treatment for stage III carcinoma of the breast. Arch Surg 122: 1430-1434, 1987
Lopez MJ, Andriole DP, Kraybill WG, Khojasteh A: Multimodal therapy in locally advanced breast carcinoma. Am J Surg 160: 669-675, 1990
Hortobagyi GN, Ames FC, Buzdar AU, Kau SW, McNeese MD, Paulus D, Hug V, Holmes FA, Romsdahl MM, Fraschini G: Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 62: 2507-2516, 1988
Swain SM, Sorace RA, Bagley CS, Danforth Jr DN, Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res 47: 3889-3894, 1987
Booser D, Hortobagyi G: Treatment of locally advanced breast cancer. Semin Oncol 19: 278-285, 1992
Singletary S, McNeese M, Hortobagyi G: Feasibility of breastconservation chemotherapy for locally advanced breast carcinoma. Cancer 69: 2849-2852, 1992
Hortobagyi GN, Blumenschein GR, Spanos W, Montague ED, Buzdar AU, Yap HY, Schell F: Multimodal treatment of locoregional advanced breast cancer. Cancer 51: 763-768, 1983
Feldman L, Hortobagyi G, Buzdar A, Ames F, Blumeschein G: Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res 46: 2578-2581, 1986
Segel M, Paulus D, Hortobagyi G: Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 169: 49-54, 1988
Cocconi G, Di Blasio B, Alberti G, Bisagni G, Botti E, Peracchia G: Problems in evaluation response of primary breast cancer to systemic therapy. Breast Cancer Res Treat 4: 309-313, 1984
Gilles R, Guinebretiere JM, Toussaint C, Spielman M, Rietjens M, Petit JY, Contesso G, Masselot J, Vanel D: Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 191: 633-638, 1994
Abraham DC, Jones RC, Jones SE, Cheek JH, Peters GN, Knox SM, Grant MD, Hampe DW, Savino DA, Harms SE: Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer 78: 91-100, 1996
Drew PJ, Kerin MJ, Mahapatra T, Malone C, Monson JR, Turnhull LW, Fox JN: Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 27: 617-620, 2001
Trecate G, Ceglia E, Stabile F, Tesoro-Tess JD, Mariani G, Zambetti M, Musumeci R: Locally advanced breast cancer treated with primary chemotherapy: comparison between magnetic imaging and pathologic evaluation of residual disease. Tumori 85: 220-228, 1999
Padhani AR, Ollivier L: The RECIST criteria: implications for diagnostic radiologists. Br J Radiol 74: 983-986, 2001
James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A, Therasse P: Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Nat Cancer Inst 91: 523-528, 1999
McNeil BJ, Hanley JA: Statistical approaches to the analysis of receiving operating characteristic (ROC) curves. Med Decision Making 4: 137-150, 1988
Schwartz GF, Birchansky CA, Komarnicky LT, Mansfield CM, Canton RI, Biermann WA, Fellin FM, McFarlane J: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast. Cancer 73: 362-369, 1994
Khanna MM, Mark RJ, Silverstein MJ, Juillard G, Lewinsky B, Guiliano AE: Breast conservation management of breast tumors 4 cm or larger. Arch Surg 127: 1038-1043, 1992
Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z: Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. Am J Coll Surg 180: 297-306, 1995
Davis PL, McCarty SK: Technologic consideration for breast tumor size assessment. MRI Clin N Am 2: 623-631, 1994a
Kuhl CK, Mielcareck P, Klaschik S, Leutner C, Wardelmann E, Gieseke J, Schild HH: Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions? Radiology 211:101-110, 1999
Orel SG, Schnall MD, LiVolsi VA, Troupin RH: Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 190: 485-493, 1994
Knopp MV, Brix G, Junkermann HJ, Sinn HP: MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy. MRI Clin N Am 2: 633-658, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Cheung, YC., Chen, SC., Su, MY. et al. Monitoring the Size and Response of Locally Advanced Breast Cancers to Neoadjuvant Chemotherapy (Weekly Paclitaxel and Epirubicin) with Serial Enhanced MRI. Breast Cancer Res Treat 78, 51–58 (2003). https://doi.org/10.1023/A:1022153327339
Issue Date:
DOI: https://doi.org/10.1023/A:1022153327339